Scientific Program
as of March 2026
Upon completion, participants will be able to:
- Describe the role of obesity and metabolic dysfunction in systemic and cutaneous inflammation
- Explain the mechanisms by which GLP-1 receptor agonists may influence immune function and inflammatory skin diseases
- Evaluate current evidence supporting the potential use of GLP-1 therapies across dermatologic, rheumatologic, gastrointestinal, and cardiometabolic conditions
- Apply emerging data on GLP-1 receptor agonists into multidisciplinary, patient-centered clinical care strategies
Wednesday, July 15, 2026
| 8:00 AM | Registration |
| 08:00 AM – 08:45 AM | Breakfast |
| 08:45 AM – 08:55 AM | Welcoming words by the Dean of the Icahn School of Medicine at Mount Sinai Eric J. Nestler, New York, NY |
| 08:55 AM – 09:00 AM | Introduction by the Organizing Commitee Emma Guttman, New York, NY James G. Krueger, New York, NY Patrick M. Brunner, New York, NY |
| 09:00 AM – 09:30 AM | Effects of obesity on the immune system – How do GLP1’s intervene? Lydia Lynch, Princeton, NJ |
| 09:30 AM – 10:00 AM | Potential role of GLP-1 in reducing inflammation in rheumatological diseases Alexis R. Ogdie, Philadelphia, PA |
| 10:00 AM – 10:30 AM | Break |
| 10:30 AM – 11:00 AM | Effect of GLP-1s on the skin and potential treatments Doris Day, New York, NY |
| 11:00 AM – 11:30 AM | Dermatology–GI cross indications and potential of GLP-1 as an add on therapy Ahuva Cices, New York, NY |
| 11:30 AM – 12:00 PM | Skin inflammaging Helen He, New York, NY |
| 12:00 PM – 12:45 PM | Lunch |
| 12:45 PM – 1:15 PM | Incorporating GLP-1’s across indications Panel Discussion |
| 1:15 PM – 1:45 PM | Skin diseases, obesity and GLP-1s James G. Krueger, New York, NY |
| 1:45 PM – 2:15 PM | Psoriasis and the Cardiometabolic Syndrome Mark Lebwohl, New York, NY |
| 2:15 PM – 2:45 PM | GLP-1’s and MASH Meena Bansal, New York, NY |
| 2:45 PM – 3:15 PM | Effects of GLP-1’s on the gut Marla Dubinsky, New York, NY |
| 3:15 PM – 3:45 PM | Break |
| 3:45 PM – 4:15 PM | The mental health impact of GLP-1s Rachel Goldman, New York, NY |
| 4:15 PM – 4:45 PM | How GLP-1s fit in treating the cardiometabolic syndrome Deepak L. Bhatt, New York, NY |
| 4:45 PM – 5:15 PM | GLP-1: The past, present and future Mark Genovese, Indianapolis, IN |
| 5:15 PM | Adjournment |
AMA PRA Category 1 accreditation
GLP-1 has been accredited with 5 AMA PRA Category 1 credits.